{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T01:02:04Z","timestamp":1770858124840,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Brown Center for Immunotherapy"},{"name":"Indiana University Health Values Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>African American men experience markedly higher prostate cancer incidence and mortality yet remain underrepresented in genomic studies aimed at identifying ancestry-associated molecular drivers of disease progression. Circulating cell-free DNA (cfDNA) provides a minimally invasive means of capturing tumor-derived genomic alterations and enables broad characterization of molecular heterogeneity. In this study, we performed comprehensive plasma cfDNA profiling in 22 African American and 66 Caucasian men with metastatic castration-resistant prostate cancer (mCRPC) to define ancestry-related differences in mutation landscapes. Across samples, we identified 281 variants within 88 genes, with African American patients exhibiting a significantly higher burden of differentially frequent mutations. Integration of Gene Ontology analysis, KEGG pathway mapping, and functional enrichment revealed ancestry-dependent perturbations in pathways central to prostate cancer biology, including PI3K\u2013AKT, MAPK, androgen signaling, DNA repair, and cell-cycle regulation. A panel of 25 genes emerged as key contributors to divergent disease mechanisms across racial groups. Several variants enriched in African American patients involved genes regulating genomic stability and treatment resistance, offering potential insight into observed clinical outcome disparities. These findings provide a comprehensive, ancestry-informed cfDNA mutational landscape in mCRPC and highlight biologically meaningful differences that may support the development of non-invasive biomarkers, improved risk stratification, and ancestry-tailored precision oncology strategies.<\/jats:p>","DOI":"10.1186\/s43556-026-00405-8","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:02:11Z","timestamp":1770854531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating cell-free DNA profiling reveals ancestry-dependent genetic variation in metastatic prostate cancer"],"prefix":"10.1186","volume":"7","author":[{"given":"Samaneh","family":"Maleknia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Hassoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil","family":"Adra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-0733","authenticated-orcid":false,"given":"Reza","family":"Shahbazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"405_CR1","doi-asserted-by":"publisher","unstructured":"Kratzer TB, Mazzitelli N, Star J, Dahut WL, Jemal A, Siegel RL. Prostate cancer statistics, 2025. CA: Cancer J Clin. 2025;75(6):485\u201397. https:\/\/doi.org\/10.3322\/caac.70028.","DOI":"10.3322\/caac.70028"},{"issue":"2","key":"405_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/gim.2017.96","volume":"20","author":"JL Caswell-Jin","year":"2018","unstructured":"Caswell-Jin JL, Gupta T, Hall E, Petrovchich IM, Mills MA, Kingham KE, et al. Racial\/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genet Med. 2018;20(2):234\u20139.","journal-title":"Genet Med"},{"key":"405_CR3","doi-asserted-by":"crossref","unstructured":"Yuan J, Hu Z, Mahal BA, Zhao SD, Kensler KH, Pi J et al. Integrated analysis of genetic ancestry and genomic alterations across cancers. Cancer Cell. 2018;34(4):549\u201360. e9.","DOI":"10.1016\/j.ccell.2018.08.019"},{"issue":"6","key":"405_CR4","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.annonc.2021.03.196","volume":"32","author":"A Jayaram","year":"2021","unstructured":"Jayaram A, Wingate A, Wetterskog D, Wheeler G, Sternberg CN, Jones R, et al. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. Ann Oncol. 2021;32(6):726\u201335.","journal-title":"Ann Oncol"},{"key":"405_CR5","doi-asserted-by":"crossref","unstructured":"Maurice-Dror C, Fonseca N, Herberts C, Fan W, Wyatt AW, Chi KN. Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2021;39(15_suppl):5049.","DOI":"10.1200\/JCO.2021.39.15_suppl.5049"},{"issue":"1","key":"405_CR6","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","volume":"15","author":"NM Fonseca","year":"2024","unstructured":"Fonseca NM, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha AJ, et al. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat Commun. 2024;15(1):1828.","journal-title":"Nat Commun"},{"issue":"7921","key":"405_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41586-022-04975-9","volume":"608","author":"C Herberts","year":"2022","unstructured":"Herberts C, Annala M, Sipola J, Ng SW, Chen XE, Nurminen A, et al. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature. 2022;608(7921):199\u2013208.","journal-title":"Nature"},{"issue":"11","key":"405_CR8","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMc2000069","volume":"383","author":"BA Mahal","year":"2020","unstructured":"Mahal BA, Alshalalfa M, Kensler KH, Chowdhury-Paulino I, Kantoff P, Mucci LA, et al. Racial differences in genomic profiling of prostate cancer. N Engl J Med. 2020;383(11):1083\u20135.","journal-title":"N Engl J Med"},{"issue":"11","key":"405_CR9","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.1172\/JCI70354","volume":"123","author":"MC Haffner","year":"2013","unstructured":"Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013;123(11):4918\u201322.","journal-title":"J Clin Invest"},{"issue":"12","key":"405_CR10","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1158\/1541-7786.MCR-20-0648","volume":"18","author":"W Liu","year":"2020","unstructured":"Liu W, Zheng SL, Na R, Wei L, Sun J, Gallagher J, et al. Distinct genomic alterations in prostate tumors derived from African American men. Mol Cancer Res. 2020;18(12):1815\u201324.","journal-title":"Mol Cancer Res"},{"issue":"5","key":"405_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41585-020-0297-9","volume":"17","author":"MC Maia","year":"2020","unstructured":"Maia MC, Salgia M, Pal SK. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nat Rev Urol. 2020;17(5):271\u201391.","journal-title":"Nat Rev Urol"},{"issue":"7","key":"405_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41585-018-0020-2","volume":"15","author":"RB Berish","year":"2018","unstructured":"Berish RB, Ali AN, Telmer PG, Ronald JA, Leong HS. Translational models of prostate cancer bone metastasis. Nat Rev Urol. 2018;15(7):403\u201321. https:\/\/doi.org\/10.1038\/s41585-018-0020-2.","journal-title":"Nat Rev Urol"},{"issue":"7","key":"405_CR13","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.3390\/cancers12071812","volume":"12","author":"P Maroni","year":"2020","unstructured":"Maroni P, Bendinelli P. Bone, a secondary growth site of breast and prostate carcinomas: role of osteocytes. Cancers. 2020;12(7):1812. https:\/\/doi.org\/10.3390\/cancers12071812.","journal-title":"Cancers"},{"issue":"4","key":"405_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","volume":"7","author":"A Ali","year":"2021","unstructured":"Ali A, Hoyle A, Haran \u00c1M, Brawley CD, Cook A, Amos C, et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2021;7(4):555\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2020.7857.","journal-title":"JAMA Oncol"},{"issue":"4","key":"405_CR15","first-page":"1","volume":"25","author":"E Archer Goode","year":"2023","unstructured":"Archer Goode E, Wang N, Munkley J. Prostate cancer bone metastases biology and clinical management. Oncol Lett. 2023;25(4):1\u201318.","journal-title":"Oncol Lett"},{"key":"405_CR16","doi-asserted-by":"publisher","unstructured":"Baldessari C, Pipitone S, Molinaro E, Cerma K, Fanelli M, Nasso C, et al. Bone metastases and health in prostate cancer: From pathophysiology to clinical implications. Cancers (Basel). 2023;15(5):1518. https:\/\/doi.org\/10.3390\/cancers15051518.","DOI":"10.3390\/cancers15051518"},{"key":"405_CR17","doi-asserted-by":"crossref","unstructured":"Pichardo CM, Ezeani A, Acevedo AM, Agurs-Collins T, Bailey-Whyte M, Dorsey TH et al. West African genetic ancestry, neighborhood deprivation, and prostate cancer. JAMA Network Open. 2024;7(9):e2433546-e.","DOI":"10.1001\/jamanetworkopen.2024.33546"},{"issue":"21","key":"405_CR18","doi-asserted-by":"publisher","first-page":"e70354","DOI":"10.1002\/cam4.70354","volume":"13","author":"R Wang","year":"2024","unstructured":"Wang R, Qu Z, Lv Y, Yao L, Qian Y, Zhang X, et al. Important roles of PI3K\/AKT signaling pathway and relevant inhibitors in prostate cancer progression. Cancer Med. 2024;13(21):e70354.","journal-title":"Cancer Med"},{"issue":"7","key":"405_CR19","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41585-023-00849-5","volume":"21","author":"JR Johnson","year":"2024","unstructured":"Johnson JR, Mavingire N, Woods-Burnham L, Walker M, Lewis D, Hooker SE, et al. The complex interplay of modifiable risk factors affecting prostate cancer disparities in African American men. Nat Rev Urol. 2024;21(7):422\u201332.","journal-title":"Nat Rev Urol"},{"issue":"5","key":"405_CR20","first-page":"e70206","volume":"8","author":"Y Feng","year":"2025","unstructured":"Feng Y, Feng Z, Li D, Gui J, Song Z, Xie X, et al. Association aamong ppolymorphisms in the aapoptosis-rrelated NKX3-1, Caspase-3, Caspase-9, and BCL-2 genes and prostate cancer susceptibility from 9706 cases and 12,567 controls. Cancer Rep. 2025;8(5):e70206.","journal-title":"Cancer Rep"},{"issue":"1","key":"405_CR21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):425. https:\/\/doi.org\/10.1038\/s41392-021-00828-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"405_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41389-019-0165-8","volume":"8","author":"F Liang","year":"2019","unstructured":"Liang F, Ren C, Wang J, Wang S, Yang L, Han X, et al. The crosstalk between STAT3 and p53\/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug\/MAPK\/PI3K\/AKT-mediated regulation of EMT and autophagy. Oncogenesis. 2019;8(10):59. https:\/\/doi.org\/10.1038\/s41389-019-0165-8.","journal-title":"Oncogenesis"},{"key":"405_CR23","doi-asserted-by":"publisher","first-page":"101235","DOI":"10.1016\/j.neo.2025.101235","volume":"70","author":"F Ahmad","year":"2025","unstructured":"Ahmad F, White M, Yamamoto K, Crooks DR, Agarwal S, Yang Y, et al. Metabolic and imaging phenotypes associated with RB1 and TP53 loss in prostate cancer. Neoplasia. 2025;70:101235. https:\/\/doi.org\/10.1016\/j.neo.2025.101235.","journal-title":"Neoplasia"},{"issue":"23","key":"405_CR24","doi-asserted-by":"publisher","first-page":"9544","DOI":"10.1158\/0008-5472.Can-10-1638","volume":"70","author":"NC Bastus","year":"2010","unstructured":"Bastus NC, Boyd LK, Mao X, Stankiewicz E, Kudahetti SC, Oliver RT, et al. Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res. 2010;70(23):9544\u20138. https:\/\/doi.org\/10.1158\/0008-5472.Can-10-1638.","journal-title":"Cancer Res"},{"issue":"1","key":"405_CR25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1186\/s12885-015-1612-3","volume":"15","author":"HT Kissick","year":"2015","unstructured":"Kissick HT, On ST, Dunn LK, Sanda MG, Asara JM, Pellegrini KL, et al. The transcription factor ERG increases expression of neurotransmitter receptors on prostate cancer cells. BMC Cancer. 2015;15(1):604. https:\/\/doi.org\/10.1186\/s12885-015-1612-3.","journal-title":"BMC Cancer"},{"issue":"10","key":"405_CR26","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/pros.23823","volume":"79","author":"J Blackburn","year":"2019","unstructured":"Blackburn J, Vecchiarelli S, Heyer EE, Patrick SM, Lyons RJ, Jaratlerdsiri W, et al. TMPRSS2-ERG fusions linked to prostate cancer racial health disparities: a focus on Africa. Prostate. 2019;79(10):1191\u20136. https:\/\/doi.org\/10.1002\/pros.23823.","journal-title":"Prostate"},{"issue":"4","key":"405_CR27","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.3390\/ijms15045388","volume":"15","author":"V Stagni","year":"2014","unstructured":"Stagni V, Oropallo V, Fianco G, Antonelli M, Cin\u00e0 I, Baril\u00e0 D. Tug of war between survival and death: exploring ATM function in cancer. Int J Mol Sci. 2014;15(4):5388\u2013409. https:\/\/doi.org\/10.3390\/ijms15045388.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"405_CR28","doi-asserted-by":"publisher","first-page":"e13210","DOI":"10.1111\/pcmr.13210","volume":"38","author":"E Broseghini","year":"2025","unstructured":"Broseghini E, Venturi F, Veronesi G, Scotti B, Migliori M, Marini D, et al. Exploring the common mutational landscape in cutaneous melanoma and pancreatic cancer. Pigment Cell Melanoma Res. 2025;38(1):e13210. https:\/\/doi.org\/10.1111\/pcmr.13210.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"405_CR29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/sj.pcan.4500674","volume":"6","author":"CD Petraki","year":"2003","unstructured":"Petraki CD, Gregorakis AK, Papanastasiou PA, Karavana VN, Luo LY, Diamandis EP. Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis. 2003;6(3):223\u20137. https:\/\/doi.org\/10.1038\/sj.pcan.4500674.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"405_CR30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/pros.23932","volume":"80","author":"L Pardy","year":"2020","unstructured":"Pardy L, Rosati R, Soave C, Huang Y, Kim S, Ratnam M. The ternary complex factor protein ELK1 is an independent prognosticator of disease recurrence in prostate cancer. Prostate. 2020;80(2):198\u2013208. https:\/\/doi.org\/10.1002\/pros.23932.","journal-title":"Prostate"},{"issue":"5","key":"405_CR31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/bioinformatics\/btp698","volume":"26","author":"H Li","year":"2010","unstructured":"Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26(5):589\u201395. https:\/\/doi.org\/10.1093\/bioinformatics\/btp698.","journal-title":"Bioinformatics"},{"key":"405_CR32","unstructured":"Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. 2012. arXiv preprint arXiv:12073907."},{"issue":"22","key":"405_CR33","doi-asserted-by":"publisher","first-page":"11189","DOI":"10.1093\/nar\/gks918","volume":"40","author":"A Wilm","year":"2012","unstructured":"Wilm A, Aw PPK, Bertrand D, Yeo GHT, Ong SH, Wong CH, et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 2012;40(22):11189\u2013201.","journal-title":"Nucleic Acids Res"},{"key":"405_CR34","doi-asserted-by":"publisher","unstructured":"Sondka Z, Dhir NB, Carvalho-Silva D, Jupe S, Madhumita, McLaren K et al. COSMIC:\u00a0a curated database of somatic variants and clinical data for cancer. Nucleic Acids Res. 2023;52(D1):D1210-D7. https:\/\/doi.org\/10.1093\/nar\/gkad986.","DOI":"10.1093\/nar\/gkad986"},{"issue":"7993","key":"405_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-023-06045-0","volume":"625","author":"S Chen","year":"2024","unstructured":"Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature. 2024;625(7993):92\u2013100. https:\/\/doi.org\/10.1038\/s41586-023-06045-0.","journal-title":"Nature"},{"key":"405_CR36","doi-asserted-by":"crossref","unstructured":"Consortium GO. The gene ontology (GO) project in 2006. Nucleic acids research. 2006;34(suppl_1):D322-D6.","DOI":"10.1093\/nar\/gkj021"},{"issue":"1","key":"405_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/pro.4218","volume":"31","author":"PD Thomas","year":"2022","unstructured":"Thomas PD, Ebert D, Muruganujan A, Mushayahama T, Albou LP, Mi H. Panther: making genome-scale phylogenetics accessible to all. Protein Sci. 2022;31(1):8\u201322.","journal-title":"Protein Sci"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00405-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00405-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00405-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:02:16Z","timestamp":1770854536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00405-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["405"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00405-8","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patient samples used in this study were collected following the approval of our institution's ethical review board, the Indiana University Human Research Protection Program (HRPP), under protocol number 12515, and in strict compliance with ethical guidelines. Informed consent was obtained from all patients prior to sample collection, ensuring they were fully informed about the study's purpose, procedures, and potential risks. All samples were de-identified, and protected health information was managed in accordance with the Health Insurance Portability and Accountability Act (HIPAA) guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}